Massay R J B, Maynard A A
Cardiac Unit, The Queen Elizabeth Hospital, St Michael, Barbados, West Indies.
West Indian Med J. 2012 Oct;61(7):743-5.
Herein, we present three cases of Pityriasis lichenoides chronica (PLC) in patients who developed the rash after use of 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA) reductase inhibitors. The patients had complete resolution after standard treatment by dermatologists and withdrawal of the offending agents. In one case, the patient had a previous episode of a similar rash that occurred with HMG-CoA reductase inhibitors use many years previously. Pityriasis lichenoides chronica is a condition of unknown aetiology. Several agents have been associated with its presentation. We postulate HMG-CoA reductase inhibition in skin presents a final common pathway for the presentation of PLC in select patients.
在此，我们报告3例慢性苔藓样糠疹（PLC）患者，他们在使用3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂后出现皮疹。经皮肤科医生的标准治疗并停用致病药物后，患者皮疹完全消退。其中1例患者曾在多年前使用HMG-CoA还原酶抑制剂时出现过类似皮疹。慢性苔藓样糠疹病因不明。已有多种药物与其发病相关。我们推测，皮肤中HMG-CoA还原酶的抑制作用是部分患者发生PLC的最终共同途径。
